ASYMCHEM (06821) Stock Price, News, Quotes-Moomoo

HK Stock MarketDetailed Quotes

06821 ASYMCHEM

Watchlist

48.000
+0.450+0.95%

Market Closed Jan 17 16:08 CST

17.65BMarket Cap20.70P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Shares Not Telling The Full Story
Simply Wall StJan 2 21:18 ET
Investors Three-year Losses Continue as Asymchem Laboratories (Tianjin) (SZSE:002821) Dips a Further 4.3% This Week, Earnings Continue to Decline
Simply Wall StDec 14, 2024 19:12 ET
Estimating The Fair Value Of Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821)
Simply Wall StNov 26, 2024 21:16 ET
Building a World-Class Synthetic Biology Lab: Asymchem's Self-Developed STAR System Empowers Protein Design
BusinesswireNov 6, 2024 11:00 ET
Why Asymchem Laboratories (Tianjin)'s (SZSE:002821) Shaky Earnings Are Just The Beginning Of Its Problems
Simply Wall StNov 5, 2024 18:08 ET
Here's What Analysts Are Forecasting For Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) After Its Third-Quarter Results
Simply Wall StOct 31, 2024 18:49 ET

Comments

Moomoo AI

Mar 4, 2024 17:15

Asymchem Laboratories (Tianjin)'s low P/E ratio may be due to investors' belief in the company's poor earnings performance. The outlook for shrinking earnings contributes to its low P/E, forming a barrier for the share price.

Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Moomoo AI

Jan 17, 2024 19:24

Asymchem Laboratories (Tianjin)'s low P/E ratio is due to predicted declining earnings. Investors see limited potential for earnings improvement, hence a higher P/E ratio isn't justified, indicating a stagnant share price.

Investors Aren't Buying Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Earnings

Spinee

Jan 17, 2024 02:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

Heat List

Overall

No Data

Investment Theme

CRO

Intraday+0.01%